Piramal Pharma Limited (IN:PPLPHARMA)
:PPLPHARMA
Want to see IN:PPLPHARMA full AI Analyst Report?
PPLPHARMA Stock Chart & Stats
₹192.65
-₹4.80(-1.92%)
At close: 4:00 PM EST
₹192.65
-₹4.80(-1.92%)
Day’s Range― - ―
52-Week Range₹132.50 - ₹220.90
Previous CloseN/A
Volume1.66M
Average Volume (3M)264.14K
Market Cap
₹232.62B
Enterprise Value₹278.13B
Total Cash (Recent Filing)₹7.44B
Total Debt (Recent Filing)₹48.51B
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 05, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)-0.18
Shares Outstanding1,329,248,200
10 Day Avg. Volume501,791
30 Day Avg. Volume264,138
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.22
Price to Sales (P/S)2.04
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.41
Revenue Forecast (FY)₹101.11B
Bulls Say, Bears Say
Bulls Say
Revenue ScalingSustained multi-year top-line growth to ~₹88.7B signals expanding commercial traction and scale across its businesses. Higher revenue base supports fixed-cost absorption, investment in capacity and R&D, and underpins the company's ability to win larger CDMO contracts and sustain hospital-generic production.
Improved Cash GenerationMaterial improvement in operating and free cash flow provides durable internal funding for capex, working capital and deleveraging. Positive FCF enhances strategic optionality to support long-term CDMO investments, commercial expansion, or targeted M&A without sole reliance on external financing.
Diversified Business ModelThree distinct revenue streams—CDMO services, hospital/critical-care generics and OTC consumer healthcare—reduce single-market dependence. Structural diversification sustains demand through product lifecycle differences and provides cross-segment resilience against regulatory or pricing pressures in any single channel.
Bears Say
Recurring Net LossesRecurrent bottom-line losses undermine retained earnings and capital accumulation, limiting internal funding for growth or deleveraging. Persistent losses reduce ability to build reserves against industry shocks and may force reliance on debt or equity raises, diluting capital efficiency over time.
Rising Debt LevelsMaterial increase in leverage raises fixed interest obligations and reduces financial flexibility. With uneven profitability, higher debt amplifies downside risk if cash generation weakens, constraining capacity to invest in capacity or absorb regulatory-related delays common in pharma manufacturing.
Profitability VolatilityWide swings in net income and inconsistent ROE indicate unstable margin capture and exposure to episodic costs or one-offs. Such volatility complicates long-term planning, makes consistent return generation uncertain, and raises execution risk for sustaining investments in CDMO capacity and new product launches.
Piramal Pharma Limited News
PPLPHARMA FAQ
What was Piramal Pharma Limited’s price range in the past 12 months?
Piramal Pharma Limited lowest stock price was ₹132.50 and its highest was ₹220.90 in the past 12 months.
What is Piramal Pharma Limited’s market cap?
Piramal Pharma Limited’s market cap is ₹232.62B.
When is Piramal Pharma Limited’s upcoming earnings report date?
Piramal Pharma Limited’s upcoming earnings report date is Aug 05, 2026 which is in 76 days.
How were Piramal Pharma Limited’s earnings last quarter?
Piramal Pharma Limited released its earnings results on Apr 28, 2026. The company reported ₹1.3 earnings per share for the quarter, beating the consensus estimate of ₹0.96 by ₹0.34.
Is Piramal Pharma Limited overvalued?
According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued.
Does Piramal Pharma Limited pay dividends?
Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.08%. See more information on Piramal Pharma Limited dividends here
What is Piramal Pharma Limited’s EPS estimate?
Piramal Pharma Limited’s EPS estimate is -0.86.
How many shares outstanding does Piramal Pharma Limited have?
Piramal Pharma Limited has 1,329,248,200 shares outstanding.
What happened to Piramal Pharma Limited’s price movement after its last earnings report?
Piramal Pharma Limited reported an EPS of ₹1.3 in its last earnings report, beating expectations of ₹0.96. Following the earnings report the stock price went down -2.637%.
Which hedge fund is a major shareholder of Piramal Pharma Limited?
Currently, no hedge funds are holding shares in IN:PPLPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Jubilant Ingrevia Ltd.
―
Syngene International Ltd.
―